Its main roles involve stimulating GLP-1 receptors, altering glucagon secretion, and boosting insulin sensitivity. Semaglutide acts as a GLP-1 (glucagon-like peptide-1) receptor agonist. This means it ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in ...

This study presents a valuable finding on the role of cholesterol-binding site on GLP-1 receptors and functionally characterizes the impact of this mutation on receptor behavior in the membrane and ...

pennmedicine.upenn.edu Background/aims Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus. Recent work showed that ...

These therapies, including dual GIP and GLP-1 receptor agonists (eg, tirzepatide), triple GIP, GLP-1, and glucagon receptor agonists (eg, retatrutide), and cagrilintide and GLP-1 receptor agonist ...

Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China ...

which in turn will hand over UBT251, a so-called triple-G asset that activates the GLP-1, GIP and glucagon receptors.

Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, University of Tuebingen, Auf der Morgenstelle 8, Tuebingen 72076, Germany IFIT Cluster of Excellence EXC ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

About UBT251UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon.